Neurological
Refine Search
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, are collaborating on a project to tackle the urgent and unmet needs of people living with mental health conditions. 4 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Pharmaceutical
US pharma major AbbVie and Hungary’s Gedeon Richter have announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. 1 November 2024
Biotechnology
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. 1 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biotechnology
Boston, USA-based biotech Axonis Therapeutics, which is focused on the development of novel neuromedicines, has announced the successful completion of an oversubscribed $115 million Series A financing. 31 October 2024
Biotechnology
US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. 30 October 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Pharmaceutical
Finnish pharma group Orion has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for long-term use. 25 October 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Biotechnology
Shares of Californian clinical-stage biotech Alto Neuroscience plummeted 70% to $4.36 yesterday, as is announced disappointing trial results for depression candidate. 24 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Pharmaceutical
Stolberg-based drugmaker Grünenthal has entered into a collaboration with fellow German groups Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine (MPI-EM) to develop novel therapies for the neurological disorder Charcot-Marie-Tooth 1A (CMT1A). 21 June 2018
Pharmaceutical
Last week, regulatory news featured, with the announcement that the US Food and Drug Administration has approved AbbVie and Roche’s Venclexta in leukemia and lymphoma indications. Also attracting attention was China’s approval of the first immuno-oncology drug, Bristol-Myers Squibb’s Opdivo. New clinical trial results were in focus, with yet another Alzheimer’s drug failure, this one for Eli Lilly and AstraZeneca’s candidate lanabecestat, and Vical’s herpes simplex virus vaccine disappointment in Phase II studies, but the company still has a positive pipeline. However, there was a positive surprise from Israel’s Galmed trial with Aramchol in non-alcoholic steatohepatitis (NASH). 17 June 2018
Biotechnology
Israeli drugmaker Teva Pharmaceutical Industries on Friday announced a change in the clinical development program of fremanezumab in chronic cluster headache. 16 June 2018
Generics
The US Food and Drug Administration on Thursday approved the first generic versions of Indivior’s top-selling opioid addiction treatment Suboxone (buprenorphine and naloxone) sublingual film for the treatment of opioid dependence. 15 June 2018
Biotechnology
US clinical-stage biotech Sage Therapeutics has entered into a strategic collaboration for the clinical development and commercialization of SAGE-217 for the treatment of major depressive disorder (MDD) and other indications in Japan, Taiwan and South Korea. 14 June 2018
Biotechnology
USA-based vTv Therapeutics saw its shares plunge 22.75% to $1.46 in pre-market trading after it revealed another disappointment in the development of its Alzheimer’s disease candidate, notching up another AD failure this week alone. 13 June 2018
Pharmaceutical
Another Alzheimer’s disease candidate looks set to be consigned to the scrap heap after failing in late-stage trials. 12 June 2018
Pharmaceutical
Ireland-headquartered Allergan has revealed positive results from a Phase IIb/III study of its oral migraine therapy atogepant. 12 June 2018
Biotechnology
US drugmaker Alexion Pharmaceuticals has entered into a partnership with Dutch biotech Complement Pharma to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. 12 June 2018
Pharmaceutical
More than half of diabetics have been treated for mental health problems, according to new research. 11 June 2018
Biotechnology
US biotech major Amgen’s Aimovig (erenumab) is forecast to be the top-selling drug in the migraine market by 2026, generating nearly $1.4 billion in sales in the seven major markets. 11 June 2018
Pharmaceutical
Danish CNS specialist Lundbeck and Japan’s Takeda Pharmaceutical today announced positive results from the pivotal study with vortioxetine in adults with major depressive disorder (MDD) conducted in Japan. 8 June 2018
Pharmaceutical
Drugmakers Pfizer and Flynn Pharma have successfully overturned fines of nearly nearly £90 million ($120 million) levied by the UK’s competition authority in 2016 over allegations of price gouging. 8 June 2018
Biotechnology
US biotech firm Biogen has turned to a Japanese company’s research as it looks to develop a new stroke drug. 7 June 2018
Biotechnology
UK gene and cell therapy group Oxford BioMedica saw its share price leap more than 19% to 862.40 pence today, after it announced a lucrative deal to commercialize its Parkinson’s disease candidate, which could be worth as much as $824 million. 6 June 2018
Biotechnology
New York’s Pfizer says it plans to invest $600 million in biotech companies via its investment vehicle, Pfizer Ventures. 6 June 2018
Biotechnology
The USA’s Institute for Clinical and Economic Review has released an Evidence Report assessing the comparative clinical effectiveness and value of three calcitonin gene-related peptide (CGRP) inhibitors for prevention of migraine attacks. 5 June 2018
Biosimilars
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval, including two orphan medicines, at its May 28-31, 2018 meeting. 2 June 2018
Biotechnology
The Johnson & Johnson unit Janssen appears to have one of the hottest prospects in neuroscience on its hands in the shape of esketamine, but that it not to say it is proving immune to encountering the challenges of this tricky therapy area. 1 June 2018
Biotechnology
CNS specialist Sage Therapeutics could have its first commercial product by Christmas. 31 May 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze